| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | BIBR-1532 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | gossypol | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.059 | 0.2 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.2 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.2 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | -0.04 | 0.2 |